News &amp; Updates

The anti-interleukin (IL)-36 receptor monoclonal antibody spesolimab not only helps treat generalized pustular psoriasis (GPP) flares but also prevent them, according to the results of the Effisayil 2 study presented at WCD 2023.

Spesolimab curbs flares in generalized pustular psoriasis

$Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease$

Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease

Tocilizumab (TCZ) may be used as an alternative treatment to antitumour necrosis factor (anti-TNF) agents for patients with Behçet disease (BD)-related uveitis and neurological manifestations, a recent study has shown.

Tocilizumab an effective substitute to anti-TNF agents in refractory Behçet disease

Does polypharmacy affect survival in older patients with haematological malignancy?

Polypharmacy does not appear to result in poorer treatment response and survival in older patients with different haematological malignancies, as shown in a study presented at the recent EHA 2023.

Does polypharmacy affect survival in older patients with haematological malignancy?

Novel hepcidin mimetic shows remarkable potential for polycythemia vera

In the three-part, phase II REVIVE study, the investigational, first-in-class hepcidin mimetic rusfertide was highly effective in regulating haematocrit levels in individuals with polycythemia vera (PV) who had a high phlebotomy burden.

Novel hepcidin mimetic shows remarkable potential for polycythemia vera

Vorasidenib may be chemo–RT-sparing in certain low-grade gliomas

The oral drug vorasidenib delays disease progression compared with placebo in patients with residual or recurrent grade 2 gliomas harbouring an isocitrate dehydrogenase 1 or 2 (IDH1 or IDH2) mutation in the phase III INDIGO trial.

Vorasidenib may be chemo–RT-sparing in certain low-grade gliomas

Eosinophil levels do not influence outcomes with triple combo asthma inhaler

07 Jul 2023

Treatment with fixed-dose asthma inhaler combination of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) helps improve lung function and reduce exacerbations as compared with MF/IND and fluticasone/salmeterol (FLU/SAL), regardless of baseline eosinophil levels, according to a post hoc analysis of the IRIDIUM study.

Eosinophil levels do not influence outcomes with triple combo asthma inhaler

07 Jul 2023

Jaktinib superior to hydroxyurea in myelofibrosis

07 Jul 2023 by

Jaktinib, a novel JAK and AVCR1 inhibitor, is more effective than hydroxyurea in patients with myelofibrosis, resulting in better spleen response with improved symptom response and less cytopenias, according to the results of a phase III study presented at EHA 2023.

Jaktinib superior to hydroxyurea in myelofibrosis

07 Jul 2023

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023

In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.

Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19

07 Jul 2023

Improved binge eating outcomes with naltrexone/bupropion? Extended treatment recommended

Individuals with binge-eating disorder (BED) and obesity who responded well to combination treatment with naltrexone plus bupropion may benefit from receiving maintenance treatment with the same combination, according to a study.

Improved binge eating outcomes with naltrexone/bupropion? Extended treatment recommended

Patient-tailored interventions improve specialty medication adherence

Patient-tailored interventions have led to significant improvements in adherence to specialty medications when compared with standard of care, according to a study

Patient-tailored interventions improve specialty medication adherence